Psilocybin vs. Ketamine for Depression: How the Two Compare in 2026
Ketamine is the only rapid-acting antidepressant currently available in clinical settings for treatment-resistant depression. Psilocybin is moving toward FDA approval for the same indication. They're often discussed as alternatives, but they work through completely different mechanisms and have different evidence bases, session experiences, side effect profiles, and access contexts. This guide explains the real differences.
The Quick Comparison
| | Psilocybin | Ketamine/Esketamine | |---|---|---| | Mechanism | 5-HT2A serotonin agonist | NMDA glutamate receptor antagonist | | Session experience | 4–6 hours; visionary/introspective | 30–45 min; dissociative/anesthetic | | Number of sessions | 1–3 in clinical trials | 6–8 initial + maintenance | | Onset of effect | Days to weeks (delayed) | Hours to 1–2 days (rapid) | | Duration of effect | Weeks to months; durable in responders | Days to weeks; requires maintenance | | Therapeutic context required | Essential | Less critical | | FDA status | IND; NDA expected 2026-2027 | Approved (esketamine/Spravato, 2019) | | Insurance coverage | None currently | Spravato sometimes covered; IV not | | Cost per treatment course | $1,200–$4,500 (Oregon service center) | $4,000–$8,000 (Spravato course) | | Abuse potential | Very low; Schedule I | Moderate; Schedule III |
Mechanisms
Psilocybin acts primarily on 5-HT2A serotonin receptors — the same receptor family as classical psychedelics (LSD, mescaline). Psilocybin in the brain produces what can be described as a "serotonergic" psychedelic state: visionary, introspective, with default mode network suppression and increased brain entropy. The therapeutic mechanism involves REBUS (Relaxed Beliefs Under Psychedelics) — the loosening of hierarchical predictive processing that maintains rigid patterns like depression.
Ketamine is an NMDA (N-methyl-D-aspartate) glutamate receptor antagonist — a fundamentally different receptor system. It produces a dissociative anesthetic state (at higher doses) or a sub-anesthetic dissociative experience at clinical doses. The proposed therapeutic mechanism involves: rapid AMPA receptor upregulation, BDNF release, and synaptic strengthening in glutamate pathways — essentially creating new synaptic connections in circuits depleted by depression. This is why ketamine works rapidly (hours to days) while psilocybin's effects are slower to manifest.
The Clinical Evidence
Ketamine/Esketamine (Spravato):
- FDA-approved for treatment-resistant depression (2019) and major depressive disorder with acute suicidal ideation (2020)
- Spravato: nasal spray, administered in certified healthcare settings, 2x/week for 4 weeks then weekly maintenance
- Significant responder rates in FDA approval trials (~50–70% response at 4 weeks), but high relapse rates without maintenance
- IV ketamine (off-label): faster, potentially more effective than nasal; not FDA-approved, not covered by insurance
Psilocybin:
- COMPASS Phase 3 data (n=233, TRD): ~35–40% response rate at week 3; 60–65% of responders maintained at week 12
- Hopkins, Imperial College Phase 2 data: strong effect sizes, with durability advantages over ketamine in responders
- Not yet FDA-approved; NDA submission expected late 2026
Key difference in durability: Ketamine's antidepressant effects typically wane within days to weeks without maintenance dosing — it's often described as requiring ongoing treatment. Psilocybin's effects in clinical responders have shown more durable benefit (12+ month follow-up) from a single or small number of sessions. However, non-responders to psilocybin have poorer outcomes than ketamine non-responders.
The Session Experience
Ketamine session (30–45 minutes): The patient reclines in a clinical chair, IV or nasal spray administered. The experience is dissociative — perception separates from the body, reality distorts, some people experience dream-like imagery or pure dissociation. It is not psychologically demanding in the way psilocybin is. Most people describe it as manageable and strange. The session is over quickly.
Psilocybin session (4–6 hours): The patient reclines with eye shades and headphones, in a carefully prepared space with two guides. The experience is deeply interior, often visionary, sometimes profoundly emotional. Confronting difficult psychological material is expected — it's part of the mechanism. The experience requires sustained engagement and psychological courage. It is considered "non-specific amplification" — whatever is psychologically present is amplified, including pain as well as insight.
Who Is Each Best For?
Ketamine may be preferable when:
- Rapid response is critical (acute suicidal ideation, acute crisis)
- Patient has psychotic features that would contraindicate psilocybin
- Patient is on medications that are difficult to taper (lithium, MAOIs)
- Insurance coverage is possible (Spravato has coverage for some)
- The patient is not prepared for or interested in a deep psychological experience
- Ongoing maintenance dosing is acceptable
Psilocybin may be preferable when:
- Patient wants a small number of sessions rather than ongoing maintenance
- The psychological and existential work is valued, not just symptom relief
- There's interest in addiction components alongside depression
- Durability of effect is a priority
- Patient is prepared for a challenging session experience
Combination and Sequential Use
A small number of clinicians are exploring sequential ketamine + psilocybin approaches — using ketamine's rapid response to stabilize severe acute depression, then transitioning to psilocybin for deeper, more durable work. This is not a standard protocol and not based on established trial data. It remains experimental but is conceptually interesting: each compound has different receptor targets and time profiles.
Current Access Comparison
Ketamine (US): IV ketamine available at ketamine clinics in most major cities; off-label, not FDA-approved, not covered by insurance. Cost: $400–$800/infusion, typically 6 infusions in initial course. Spravato (esketamine): FDA-approved nasal spray, administered in certified clinics, sometimes covered by insurance for TRD.
Psilocybin (US): Legal at licensed service centers in Oregon and Colorado. Clinical trials at academic sites. No FDA approval or insurance coverage yet.
Resources
- ClinicalTrials.gov: search "psilocybin depression" and "ketamine depression"
- COMPASS Pathways: compasspathways.com — psilocybin TRD regulatory status
- Ketamine Advocacy Network: ketamineadvocacynetwork.org — ketamine access resources
- Oregon Health Authority: psilocybinservices.oregon.gov — licensed psilocybin service centers